Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
Mediators Inflamm. 2013;2013:808470. doi: 10.1155/2013/808470. Epub 2013 May 27.
This study aimed at exploring innate and adaptive immunity in allergic asthma by investigation of mRNA expression of pattern recognition receptors, T-cell-specific cytokines, and transcription factors. Mouse models for mild and severe asthma, with similar pathological characteristics observed in humans, were used to study the involved inflammatory markers as a first step in the development of phenotype-directed treatment approaches. In the mild model, mice were sensitized to ovalbumin-Imject Alum and challenged with ovalbumin. In the severe model, mice were sensitized to trinitrophenyl-conjugated ovalbumin and challenged with trinitrophenyl-ovalbumin/IgE immune complex. Pulmonary airway inflammation and mRNA expression of Toll-like receptors (TLRs), NOD-like receptors (NLRs), T cell cytokines, and transcription factors in lung tissue were examined. Different mRNA expression profiles of TLRs, NLRs, T cell cytokines, and transcription factors were observed. In the mild model, Il10 showed the largest increase in expression, whereas in the severe model, it was Inf γ with the largest increase. Expression of Tbet was also significantly increased in the severe model. Inflammation and immunity are differentially regulated in mild and severe experimental asthma. This preclinical data may help in directing clinical research towards a better understanding and therapy in mild and severe asthmatic patients.
本研究旨在通过调查模式识别受体、T 细胞特异性细胞因子和转录因子的 mRNA 表达,探索过敏性哮喘的固有和适应性免疫。使用具有与人类相似病理特征的轻度和重度哮喘小鼠模型,作为开发表型定向治疗方法的第一步,研究涉及的炎症标志物。在轻度模型中,小鼠用卵清蛋白-Imject Alum 致敏,并以卵清蛋白进行攻毒。在重度模型中,小鼠用三硝基苯-卵清蛋白缀合物致敏,并以三硝基苯-卵清蛋白/IgE 免疫复合物进行攻毒。检测肺气道炎症和肺组织中 Toll 样受体 (TLR)、NOD 样受体 (NLR)、T 细胞细胞因子和转录因子的 mRNA 表达。观察到 TLRs、NLRs、T 细胞细胞因子和转录因子的不同 mRNA 表达谱。在轻度模型中,IL10 的表达增加最大,而在重度模型中,IFNγ 的表达增加最大。Tbet 的表达在重度模型中也显著增加。在轻度和重度实验性哮喘中,炎症和免疫受到不同的调节。这些临床前数据可能有助于指导临床研究,以更好地理解和治疗轻度和重度哮喘患者。